Vividion Therapeutics, Inc.

Earlier this month, we participated in the San Diego Festival of Science and Engineering at Petco Park, an event dedicated to sparking curiosity and innovation in science, technology, engineering, arts, and math (STEAM) across the local community. Our team had a wonderful time connecting with students, parents, and educators to share our mission of improving the lives of patients with cancer and immunologic diseases. It was inspiring to see so many young minds excited about the future of science – especially during our interactive experiment! We firmly believe that fostering curiosity helps build the innovators of tomorrow. Thank you to Generation STEAM for organizing such an impactful event and to all the volunteers who made this experience possible. Check out some highlights from the event below. Biocom California #STEAMGivesBack #TeamVividion  #CancerResearch #Immunology

We recently welcomed our new colleagues from Tavros Therapeutics to Vividion HQ for a series of lively conversations about the future and some unparalleled San Diego hospitality! Tavros co-founder Eoin McDonnell provided an enlightening overview of functional genomics and what his team has accomplished to uncover druggable vulnerabilities in tumor cells. He then joined our CSO Matt Patricelli to discuss the new opportunities we are excited to pursue as we integrate our respective capabilities within Vividion’s powerful drug discovery platform. #TeamVividion

Gender equality in science is crucial for building a better future for all. At #TeamVividion, we’re proud to support and empower women in science across our organization. Their commitment, creativity, and leadership are essential to our success and key to driving groundbreaking advancements in drug discovery. By fostering a culture of inclusion, mentorship, and collaboration, we create an environment where talented women scientists can thrive and lead in meaningful ways. Today on International Day of Women and Girls in Science, we honor the contributions of all the exceptional women scientists here at Vividion who are shaping the future. Here we share highlights from six of them: Cindy Jun Shi, Beibei Cai, beatrix bartok, Junko Tamiya, Sarah Ur, and Melissa Hoffman. Learn more about their scientific journeys, the impact of their work, why they value mentorship, and how they are paving the way for future advancements in healthcare. #WomenInSTEM #CancerResearch #ImmunologyResearch #DrugDevelopment #February11

#TeamVividion is united in our mission to discover and develop new treatments for patients facing a cancer diagnosis. This #WorldCancerDay, we’re advancing precision oncology to target the root causes of hard-to-treat cancers and transform patient outcomes. Inspired by this year’s theme, “United by Unique,” we place the individual patient at the center of treatment. Every cancer journey is personal, and we believe that compassionate, people-centered approaches lead to the best results. We’re developing next-generation therapies that address the unique needs of each patient, by directly targeting key drivers of their tumors. Learn more about our pipeline of potential first-in-class therapies and how we’re shaping the future of cancer research: https://bit.ly/42vzVje #UnitedbyUnique #CancerResearch

We’re thrilled to announce the promotion of Jean Bemis to Chief Operating Officer! Jean has been on #TeamVividion since 2017, serving as Senior Vice President of R&D Operations and Alliances since 2022.  Throughout her time at Vividion, Jean has played an essential role in the advancement of our discovery engine and the progression of our clinical-stage pipeline. We look forward to our continued collaboration together as we drive forward our mission to transform patient care.     Congratulations, Jean! Learn more in today’s release: https://bit.ly/3WteITi     #CancerResearch #ImmunologyResearch #DrugDevelopment #Biotechnology

Tavros Therapeutics is now part of Vividion! Today we announced that our collaborators at Tavros Therapeutics are joining Vividion, a step that will greatly expand our functional genomics expertise and strengthen our chemoproteomics drug screening capabilities, with the potential to open a vast new set of undrugged targets. Welcome to Team Vividion! More in today’s release: https://bit.ly/4j5rTDE #TeamVividion #CancerResearch #ImmunologyResearch #DrugDevelopment #Biotechnology 

2024 has been a transformative year for #TeamVividion, marked by advancements across our portfolio and the growth of our team and capabilities. Top highlights include:    - Progressing our two Phase 1 clinical trials evaluating KEAP1 activator VVD-037 in NRF2-activated solid tumors and STAT3 inhibitor VVD-850 in STAT3-driven hematologic cancers and solid tumors - Advancing novel targets and small molecule modulators across our oncology and immunology pipeline and demonstrating our steadfast commitment to innovation - Announcing our new global R&D center in San Diego, which is set to increase our chemoproteomics screening capacity by 50%, allowing us to pursue a broader range of previously undrugged targets - Being recognized as a Top Workplace by The San Diego Union-Tribune for the third year in a row!   Driving all our achievements is our mission to improve the lives of patients with cancer and immunologic diseases and this is what will power our momentum into 2025. Thank you to our talented team for their dedication and commitment. Together, we are shaping a brighter future.    Wishing you a happy and peaceful holiday season – we look forward to reconnecting in 2025!    #CancerResearch #Immunology #Biotechnology #SanDiegoBiotech

As we observe Crohn’s & Colitis Week, we’re reminded of the urgent need for innovative solutions in immunology, specifically in inflammatory diseases such as Crohn’s disease and ulcerative colitis. We are developing selective small molecules that have the potential to treat a diverse range of conditions by reducing harmful inflammation and enhancing cellular protective mechanisms. Our novel KEAP1 and STAT3 inhibitors hold great potential for treating these types of chronic conditions. We believe that our approach has the potential to transform the treatment landscape for inflammatory bowel diseases, offering hope for patients who have long dealt with limited treatment options. #TeamVividion #Immunology

We’re excited to announce that Vividion has been recognized as a Top Workplace for 2024 by the The San Diego Union-Tribune, marking our third consecutive year of this honor!   A sincere thank you to the incredible Vividion team – your dedication and passion drive our mission to unlock new solutions for patients facing cancers and immune disorders. This achievement wouldn’t be possible without your invaluable talent and commitment to our shared goals.   Here’s to our amazing and talented employees who make Vividion a great place to work!   #TeamVividion #SanDiegoBiotech #SanDiegoLifeSciences #Biotechnology

November is #LungCancerAwarenessMonth, a time to recognize and raise awareness of lung cancer, the leading cause of cancer deaths in the U.S. There is a critical need to improve treatment for this devastating disease that typically has a poor prognosis. At Vividion we are dedicated to addressing this substantial unmet need by developing novel treatments to important targets with no existing therapeutics. Our team is targeting both the KEAP1-NRF2 and STAT3 pathways in new ways. These pathways play essential roles in the growth and resistance of many solid tumors, including non-small cell lung cancer (#NSCLC), which accounts for most of all lung cancer cases. Our lead candidates VVD-037 and VVD-850, which we are currently evaluating in Phase 1 clinical trials, hold the potential to dramatically shift the treatment paradigm for NRF2- and STAT 3-activated cancers, including lung cancer. #TeamVividion #CancerResearch